Canaccord Genuity Maintains Buy on TELA Bio, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Caitlin Cronin maintains a Buy rating on TELA Bio (NASDAQ:TELA) with a $14 price target.
July 25, 2024 | 1:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity's analyst Caitlin Cronin has reaffirmed a Buy rating on TELA Bio with a $14 price target, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a specific price target of $14 by a reputable analyst suggests positive sentiment and confidence in TELA Bio's future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100